2017 American Transplant Congress
Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation.
Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France
Donor-specific anti-HLA antibody (DSA)-mediated rejection (AMR) is a main cause of graft loss after kidney transplantation. Non-adherence is a risk factor for AMR and graft…2017 American Transplant Congress
Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status.
Introduction. Complement dependent cytotoxicity, first described in 1969 is the only functional assay studying complement activation. C3d assay is developed recently to study complement activation…2017 American Transplant Congress
Even with National Sharing, the Prospects of a 100% Sensitized Patient Receiving a Transplant Vary Dramatically Depending on the Precise CPRA Value.
1UNOS, Richmond, VA; 2Stanford Univ, Palo Alto, CA; 3Emory Univ Hosp, Atlanta, GA
Background: In the Kidney Allocation System (KAS), CPRA of 99% & 100% candidates receive regional and national priority. This broader sharing, along with adoption of…2017 American Transplant Congress
Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens.
Background: Presence of anti-HLA donor specific antibodies (DSAs) has been associated with inferior kidney transplant outcomes. Identification of risk factors for de novo DSAs could…2017 American Transplant Congress
Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes.
Introduction. Complement activating donor specific antibodies may be associated with worse outcomes in a cohort of patients who have undergone HLA-AIT. We looked for differences…2017 American Transplant Congress
Differential Suppressive Effects of Costimulatory Blockade (CD28/B7), Anti-IL6R, Bruton's Tyrosine Kinase and Janus Kinase Inhibition on De Novo vs. Recall Alloantibody Responses: Are Combined Drug Therapy Approaches Desirable?
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose: Preformed and de novo donor specific antibodies (DSA) contribute significantly to demise of allograft functions. There is no approved therapies for prevention or treatment…2017 American Transplant Congress
Experience with the Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Kidney Allograft Recipients.
Donor specific antibodies (DSA) create an impenetrable immunologic barrier to transplantation. Current rx aimed at modification of DSAs are not effective in the most HS…2017 American Transplant Congress
Activated Th1 and Th17 cTFH Phenotype Correlates with DSA Production in Kidney Transplant Recipients.
University of Pittsburgh, Starzl Transplantation Institute, Pittsburgh
Donor-specific anti-HLA antibodies (DSA) represent an important biomarker for acute rejection and are a major cause of long-term graft failure after kidney transplantation (KTx). The…2017 American Transplant Congress
Healthcare Resource Utilization for Patients with Donor-Specific Antibodies Post-Kidney Transplantation.
Formation of de novo donor-specific antibodies (dnDSA) against human leukocyte antigens (HLA) contributes to inferior kidney transplant (KT) outcomes. No data exist on healthcare resource…2017 American Transplant Congress
Elevated Serum Lipase Levels in Simultaneous Pancreas and Kidney Transplantation May Indicate Anti-HLA Donor Specific Antibody Response.
Background: Development of anti-HLA donor specific antibodies (DSAs) has been associated with inferior pancreas transplant outcomes. We analyzed data for pancreas and kidney transplant recipients…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 40
- Next Page »